Perjeta (pertuzumab) / Roche 
Welcome,         Profile    Billing    Logout  
 80 Diseases   208 Trials   208 Trials   5617 News 


«12...2829303132333435363738...7172»
  • ||||||||||  Irene (pyrotinib) / Jiangsu Hengrui Medicine
    Review, Journal, IO biomarker:  Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations. (Pubmed Central) -  Oct 31, 2021   
    The most encouraging data come from phase II studies that evaluated the antibody-drug conjugates (ADCs) ado-trastuzumab-emtansine and trastuzumab-deruxtecan in patients with HER2-mutant NSCLC, with response rates of 50% and 62%, respectively...Moreover, a paradigm shift from monotherapies towards combinations of agents with distinct mechanisms of action, such as ADCs with irreversible TKIs or immune checkpoint inhibitors, is already taking place and will change the therapeutic landscape of HER2-driven NSCLC. This paper provides a practical, concise and updated review on the therapeutic strategies in NSCLC with HER2 molecular alterations.
  • ||||||||||  Perjeta (pertuzumab) / Roche
    [VIRTUAL] A Light Gradient Boosting Machine-Enabled Early Prediction of Cardiotoxicity for Breast Cancer Patients (McCormick Place West, Outside Room W375) -  Oct 30, 2021 - Abstract #ASTRO2021ASTRO_859;    
    The patients who received chemotherapy or targeted therapy using epicorubicin, doxorubicin, evacizumab and pertuzumab were more vulnerable to severe cardiotoxicities than others. The LightGBM framework proposed herein affords a means to use EMR data to individualize the prediction of severe cardiotoxicities at point of care of patients with breast cancer receiving chemoradiotherapy, which can facilitate the identification of patients for whom early intervention are warranted before the therapy, thus potentially improving the utility of chemoradiotherapy for breast cancer from a precision treatment perspective.
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Journal:  Comparison of HER2-Targeted Antibodies for Fluorescence-Guided Surgery in Breast Cancer. (Pubmed Central) -  Oct 30, 2021   
    In vivo HER2 specificity was confirmed by immunohistochemical staining of resected tumors and normal tissues. We showed for the first time that fluorescent trastuzumab and pertuzumab immunoconjugates have similar NIRF imaging performance and demonstrated the possibility of performing HER2-targeted FGS with agents that possess distinct epitope specificity.
  • ||||||||||  Perjeta (pertuzumab) / Roche
    Clinical, Journal:  A Light Gradient Boosting Machine-Enabled Early Prediction of Cardiotoxicity for Breast Cancer Patients. (Pubmed Central) -  Oct 29, 2021   
    No abstract available The LightGBM framework proposed herein affords a means to use EMR data to individualize the prediction of severe cardiotoxicities at point of care of patients with breast cancer receiving chemoradiotherapy, which can facilitate the identification of patients for whom early intervention are warranted before the therapy, thus potentially improving the utility of chemoradiotherapy for breast cancer from a precision treatment perspective.
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Trial completion date, Trial primary completion date, IO biomarker, Metastases:  Vaccine Therapy in Treating Patients With Metastatic Solid Tumors (clinicaltrials.gov) -  Oct 27, 2021   
    P1,  N=100, Recruiting, 
    Concurrent treatment with T-DM1 and SRS may be associated with higher rates of radionecrosis. Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Enrollment change, Trial termination:  Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer (clinicaltrials.gov) -  Oct 26, 2021   
    P2,  N=7, Terminated, 
    Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022 N=75 --> 7 | Suspended --> Terminated; Data Safety Monitoring Board is in agreement with the study findings so far and the stopping rule has been met, which suspends the study treatment arms in March 2021.
  • ||||||||||  Kadcyla (ado-trastuzumab emtansine) / Roche, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
    Establishment and characterization of two simultaneously developed T-DM1-resistant, ER+/HER2+ XPDX models from the same patient with differential in vivo sensitivity to trastuzumab deruxtecan (DS-8201a) (Hall 1) -  Oct 26, 2021 - Abstract #SABCS2021SABCS_1263;    
    Methods : ST4480B and ST4480C were established from a 70-year-old Caucasian female with ER+/HER2+ metastatic breast cancer pretreated with chemotherapy and targeted agents including T-DM1 for nine months followed by capecitabine/trastuzumab/tucatinib combination for one year prior to sample collections...For in vivo studies, both models were evaluated with several chemotherapy and targeted agents alone and in combination including: trastuzumab, pertuzumab, T-DM1, DS-8201a, neratinib, tucatinib, alpelisib, everolimus, and irinotecan...Conclusion : We established two XPDX models representing T-DM1-resistant, ER+/HER2+ breast cancer from both tissue and fluid samples collected simultaneously from the same patient which were found differentially responsive to DS-8201a. These models can be utilized as a valuable tool in better understanding innate resistance to DS-8201a.
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Continuous glucose monitoring and hyperglycemia during chemotherapy for early-stage breast cancer (Hall 1) -  Oct 26, 2021 - Abstract #SABCS2021SABCS_1240;    
    P=N/A
    It is currently unknown if HG during chemotherapy is a modifiable risk factor for short and long-term BC treatment toxicities including neuropathy. Understanding glucose trends in this setting will help determine a successful intervention for HG during chemotherapy which may reduce short and long-term treatment toxicities.
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Antibody responses after SARS-CoV-2 mRNA vaccination in breast cancer patients (Hall 1) -  Oct 26, 2021 - Abstract #SABCS2021SABCS_1067;    
    All breast cancer patients on endocrine therapy or trastuzumab ± pertuzumab without chemotherapy (n=35) had anti-S Ab titer ≥ 500 U/mL. Patients on cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) appeared to have low level of anti-S Ab with 28.6% (n=4/14) had anti-S Ab titer ≤ 500 U/mL.
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Predicted financial impact of continued HER2-directed therapy in metastatic breast cancer: What is the financial toxicity in a public payer healthcare system? (Stars at Night 3/4) -  Oct 26, 2021 - Abstract #SABCS2021SABCS_1001;    
    These two databases with queried and cross referenced to identify patients who received any HER2Rx for MBC dispensed by BC Cancer between 2013 and 2018, in the era where trastuzumab plus pertuzumab and TDM-1 were standard options and publically available...As funding policies adapt to the evolving treatment landscape for patients with HER2 positive MBC, we can expect a significant increase in cost per patient in this setting with conservative estimates of $44000 per patient above current costs. As the cost of novel therapies are likely to be higher than currently available biosimilars, there will be significant implications for both private payer and public payer healthcare systems.
  • ||||||||||  zanidatamab (ZW25) / Zymeworks
    Zanidatamab (ZW25), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) for HER2-positive breast cancer (BC): Results from a phase 1 study (Hall 1) -  Oct 26, 2021 - Abstract #SABCS2021SABCS_774;    
    P1
    Methods : Pts with locally advanced and/or metastatic HER2‑positive (immunohistochemistry [IHC] 3+ or IHC 2+/fluorescence in situ hybridization+) BC who received prior trastuzumab (tras), pertuzumab (pert), and T-DM1 were enrolled...Zani (20 mg/kg Q2W or 30 mg/kg Q3W) was administered in combination with paclitaxel (pac), capecitabine (cap), or vinorelbine (vin)...These data support further investigation of zani as a novel therapeutic for these pts. The cap and vin cohorts continue to enroll, and additional cohorts are evaluating zani ± chemo in combination with tucatinib.
  • ||||||||||  Kadcyla (ado-trastuzumab emtansine) / Roche, Nerlynx (neratinib) / Puma, Knight Therap, Pierre Fabre, Perjeta (pertuzumab) / Roche
    Estimating the long-term risk of recurrence in patients receiving HER2-targeted agents in HER2+ early-stage breast cancer (ESBC) (Hall 1) -  Oct 26, 2021 - Abstract #SABCS2021SABCS_743;    
    Results of our simulation suggest that patients with HER2+ ESBC experience a range of reductions in distant recurrence from HER2-targeted agents, depending on baseline risk (pCR and hormone receptor status), and treatment effect. Epidemiologic modeling may be a useful method to estimate long-term outcomes and facilitate evaluation across disparate clinical trials.
  • ||||||||||  Kadcyla (ado-trastuzumab emtansine) / Roche, Nerlynx (neratinib) / Puma, Knight Therap, Pierre Fabre, Perjeta (pertuzumab) / Roche
    Assessment of risk factors for HER2+ breast cancer recurrence: A literature review (Hall 1) -  Oct 26, 2021 - Abstract #SABCS2021SABCS_722;    
    Finally, RCB correlated strongly with a risk of progression in patients with HER2+ EBC. Patients who have these risk factors could potentially benefit from additional treatments for their early-stage disease in an effort to reduce their risk of recurrence.
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Characterization of the tumor microenvironment in patients with hormone receptor positive, HER2 negative early breast cancer (Hall 1) -  Oct 26, 2021 - Abstract #SABCS2021SABCS_668;    
    Higher stromal densities of CD3+, CD8+, and CD3+CD8-FOXP3- TIL subsets were associated with pCR by qmIF and further analysis revealed the presence and proximity of lymphocyte subpopulations correlated with pCR, suggesting that spatial relationships between these populations within the TME contributes to sensitivity to NACT. The lack of association between TILs and pCR in our cohort by standard H&E is likely due to small numbers; however, significance was seen by qmIF, indicating this method as a potentially more sensitive approach to this analysis.
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Single-cell sequencing of the blood T cell repertoire before and after trastuzumab treatment in early stage HER2+ breast cancer (Hall 1) -  Oct 26, 2021 - Abstract #SABCS2021SABCS_634;    
    To characterize T cell response in trastuzumab plus chemotherapy treated patients, we profiled peripheral CD3+ T cells using 10x Genomics VDJ single-cell sequencing in paired samples from five patients with HER2+ breast cancer.   Patients had stage IIA (n=2), stage IIIC (n=2) or stage IV (n=1) breast cancer and were treated with preoperative docetaxel, carboplatin, trastuzumab, pertuzumab (TCHP). Single-cell sequencing enables high-resolution characterization of immune cell subsets and represents a promising approach to assess the immune response to trastuzumab and other cancer therapeutics.   In this study, single-cell sequencing of peripheral CD3+ T cells identified clonal expansions in activated CD8+ and CD4+ T cells in HER2+ breast cancer patients who had a pCR with preoperative TCHP treatment. These data are consistent with the model that T cells play a key role in trastuzumab-mediated tumor control, and warrant further investigation in a larger sample population.